ARCH Venture Management, LLC
In its 13F for Q2 2025 (holdings as of June 30, 2025, filed August 14, 2025), ARCH Venture Management, LLC reported 11 stock positions worth $299.1 million. Its top holding was Beam Therapeutics (BEAM) at 25.8% of the portfolio, followed by Vir Biotechnology (VIR, 21.8%) and Maze Therapeutics (MAZE, 16.9%). Compared with Q1 2025, it opened 3 new positions and sold out of 1. The biggest buy was a new position in Vir Biotechnology (VIR) and the biggest sale an exit from Cero Therapeutics.
- Most Recent 13F
- Q2 2026
- Location
- CHICAGO, IL
- CIK
- 0001274403
- Portfolio Value
- $299.1M (Q2 2025)
- SEC Filing
- 0001012975-25-000444 ↗ filed Aug 14, 2025
Holdings Value
Holdings 11 stocks · $299.1M
| BEAM Beam Therapeutics Inc. | 25.82% | 4,540,132 | $77.2M | No change |
| VIR Vir Biotechnology Inc. | 21.76% | 12,916,663 | $65.1M | New |
| MAZE Maze Therapeutics Inc. | 16.91% | 4,120,053 | $50.6M | No change |
| RAPP Rapport Therapeutics Inc. | 14.19% | 3,728,738 | $42.4M | No change |
| VERV Verve Therapeutics Inc. | 7.54% | 2,008,809 | $22.6M | No change |
| LYEL Lyell Immunopharma Inc. | 5.39% | 1,820,634 | $16.1M | New |
| ERAS Erasca Inc. | 4.71% | 11,055,554 | $14.1M | No change |
| GOSS Gossamer Bio Inc. | 3.31% | 8,055,916 | $9.9M | No change |
| QTTB Q32 Bio Inc. | 0.16% | 320,482 | $478K | No change |
| UNBX Unity Biotechnology Inc. | 0.13% | 1,004,817 | $386K | No change |
| CERO Cero Therapeutics Holdings I | 0.07% | 22,389 | $216K | New |
Portfolio Sells Q1 2025 → Q2 2025
| CERO THERAPEUTICS HLDGS INC | Sold out | 0.00% | −0.01 |
Portfolio Buys Q1 2025 → Q2 2025
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 12 | $1.1B | PBLS, BEAM, RAPP, SPTX, ERAS |
| Q1 2026 | 10 | $677.1M | MAZE, RAPP, VIR, ERAS, BEAM |
| Q4 2025 | 9 | $651.7M | MAZE, BEAM, RAPP, LYEL, VIR |
| Q3 2025 | 9 | $492.4M | RAPP, BEAM, MAZE, VIR, LYEL |
| Q2 2025 | 11 | $299.1M | BEAM, VIR, MAZE, RAPP, VERV |
| Q1 2025 | 9 | $206.2M | BEAM, MAZE, RAPP, ERAS, VERV |
| Q4 2024 | 9 | $230.2M | BEAM, RAPP, ERAS, VERV, GOSS |
| Q3 2024 | 9 | $260.6M | BEAM, RAPP, ERAS, QTTB, VERV |
| Q2 2024 | 9 | $266.0M | BEAM, RAPP, ERAS, VERV, GOSS |
| Q1 2024 | 8 | $80.3M | VERV, ERAS, GOSS, DNLI, QTTB |